南京威尔药业集团股份有限公司 2024 年度独立董事述职报告 作为南京威尔药业集团股份有限公司（以下简称"公司"）的第三届董事会独 立董事，本人严格按照《公司法》《上市公司治理准则》《上市公司独立董事管 理办法》等法律法规以及《公司章程》《公司独立董事工作制度》等规定和要求， 切实履行忠实勤勉义务，充分发挥独立董事作用。现将本人 2024 年度履职情况 报告如下： 管亚梅：1970 年出生，中国国籍，无境外永久居留权，博士研究生学历。 1993 年 8 月至今就职于南京财经大学，目前担任南京财经大学会计学院教授， 兼任苏州海陆重工股份有限公司独立董事。2023 年 5 月至今，担任公司独立董 事。 经自查，本人符合中国证监会《上市公司独立董事管理办法》《上海证券交 易所上市公司自律监管指引第1 号——规范运作》中关于独立董事独立性的要求， 不存在影响独立性的情况。 报告期内，本人积极参与董事会决策并对所议事项发表明确意见；对公司与 其控股股东、实际控制人、董事、高级管理人员之间的潜在重大利益冲突事项进 行监督，促使董事会决策符合公司整体利益，保护中小股东合法权益；对公司经 营发展提供专业、客观的建议，促进提升 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 349.73 million, representing a 6.03% increase compared to CNY 329.83 million in the same period last year[4]. - Net profit attributable to shareholders was CNY 36.59 million, up 5.73% from CNY 34.60 million year-on-year[4]. - Total operating revenue for Q1 2025 reached ¥349,725,188.55, an increase of 6.4% compared to ¥329,832,361.62 in Q1 2024[17]. - Net profit for Q1 2025 was ¥35,766,178.54, representing a 6.7% increase from ¥33,516,432.21 in Q1 2024[18]. - Earnings per share for Q1 2025 were ¥0.27, compared to ¥0.26 in Q1 2024, indicating a slight improvement[18]. Cash Flow - The net cash flow from operating activities decreased by 24.93% to CNY 22.21 million, down from CNY 29.59 million in the previous year[4]. - In Q1 2025, the cash inflow from operating activities was CNY 268,677,131.12, a decrease of 1.18% compared to CNY 273,321,097.29 in Q1 2024[21]. - The net cash flow from operating activities in Q1 2025 was CNY 22,211,455.90, down 25.06% from CNY 29,588,625.58 in Q1 2024[21]. - The cash outflow for investing activities in Q1 2025 totaled CNY 50,525,198.83, significantly higher than CNY 14,949,433.43 in Q1 2024[22]. - The net cash flow from investing activities was -CNY 49,625,198.83 in Q1 2025, compared to -CNY 12,034,860.57 in Q1 2024, indicating increased investment expenditures[22]. - Cash inflow from financing activities in Q1 2025 was CNY 121,000,000.00, up 51.25% from CNY 80,000,000.00 in Q1 2024[22]. - The net cash flow from financing activities improved to CNY 23,604,271.83 in Q1 2025, compared to a negative CNY 28,831,323.60 in Q1 2024[22]. - The ending cash and cash equivalents balance as of Q1 2025 was CNY 243,388,554.83, an increase from CNY 146,935,955.31 in Q1 2024[22]. Assets and Liabilities - Total assets at the end of Q1 2025 reached CNY 2.42 billion, reflecting a 1.81% increase from CNY 2.38 billion at the end of the previous year[6]. - Total assets as of the end of the reporting period were ¥2,423,991,651.70, compared to ¥2,380,913,919.67 at the end of the previous period, an increase of 1.8%[14]. - Total liabilities amounted to ¥679,504,636.68, slightly up from ¥672,715,662.08, reflecting a 1.2% increase[14]. - Non-current assets totaled ¥1,688,996,630.37, an increase from ¥1,663,708,867.64, indicating a growth of 1.5%[14]. - The company reported a decrease in accounts payable to ¥91,037,461.15 from ¥98,757,278.22, a reduction of 7.3%[14]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,012, with no preferred shareholders[9]. - The top ten shareholders collectively hold 70.12% of the company's shares, with the largest shareholder, Wu Renrong, owning 13.68%[9]. Expenses - Total operating costs for Q1 2025 were ¥307,861,914.39, up from ¥290,059,404.32 in Q1 2024, reflecting a year-over-year increase of 6.3%[17]. - Research and development expenses increased to ¥18,198,856.61 in Q1 2025, up from ¥15,768,635.95 in Q1 2024, marking a growth of 15.4%[17]. - The cash outflow for employee compensation in Q1 2025 was CNY 55,445,080.19, an increase of 15.06% from CNY 48,087,072.98 in Q1 2024[21]. - The company reported a decrease in tax payments, with CNY 14,492,378.79 in Q1 2025 compared to CNY 19,139,293.68 in Q1 2024, reflecting a 24.06% reduction[21]. Other Financial Metrics - The weighted average return on equity was 2.13%, a slight decrease of 0.03 percentage points from 2.16% in the previous year[4]. - The company reported a significant increase in prepayments, which rose by 36.96% due to higher raw material prepayments[7]. - Other receivables decreased by 35.26%, primarily due to a reduction in export tax refunds[7]. - Long-term borrowings increased by 57.14%, attributed to new medium to long-term bank loans[7].

Financial Performance - In 2024, the company achieved a net profit attributable to shareholders of 146.42 million yuan, an increase of 30.50% compared to 2023[5]. - The total operating revenue for 2024 was 1.30 billion yuan, reflecting a year-on-year growth of 12.19%[21]. - The net cash flow from operating activities reached 221.79 million yuan, up 84.45% from the previous year[21]. - The company's total assets as of December 31, 2024, amounted to 2.38 billion yuan, a 4.48% increase from the end of 2023[21]. - The basic earnings per share for 2024 were 1.08 yuan, representing a 30.12% increase compared to 2023[22]. - The weighted average return on equity rose to 8.94%, an increase of 1.55 percentage points from the previous year[22]. - The cumulative undistributed profits as of December 31, 2024, were 555.70 million yuan[5]. - The company reported a net profit of 30.77 million yuan for the parent company in 2024, with cumulative undistributed profits of 561.21 million yuan[5]. Revenue and Sales Growth - The company achieved operating revenue of 1,296.75 million RMB in 2024, representing a year-on-year growth of 12.19%[29]. - Sales volume of synthetic lubricating base oil grew by 13.17%, with sales revenue increasing by 9.53%[30]. - The sales volume of pharmaceutical excipients increased by 19.23%, and sales revenue rose by 15.44%[31]. - Revenue from synthetic lubricating base oil was ¥887,290,773.05, with a gross margin of 21.02%, reflecting an increase of 0.96 percentage points[58]. - The pharmaceutical excipients segment generated ¥336,150,944.64 in revenue, achieving a gross margin of 49.58%, up by 2.13 percentage points[58]. Research and Development - R&D expenses amounted to 71.56 million RMB, up 28.60%, accounting for 5.52% of operating revenue[33]. - The company has established multiple national and provincial-level R&D platforms, enhancing its innovation capabilities[46]. - The company is committed to innovation-driven development, focusing on process technology improvements and establishing a leading green pharmaceutical materials production base[38]. - The company focuses on developing high-safety, multifunctional pharmaceutical excipients and high-performance synthetic lubricating base oils, providing quality solutions and technical services to clients[43]. - The company has implemented a comprehensive procurement management system to optimize its supply chain and production planning[89]. Strategic Initiatives and Acquisitions - The company successfully acquired Shengwei New Materials, enhancing its strategic resource reserves[34]. - The company initiated trial production of a 5800t/a POE ester expansion project, expected to provide additional capacity for lubricating base oil[34]. - The company acquired a subsidiary, Nanjing Shengwei New Materials Technology Co., Ltd., with a registered capital of 20 million RMB, expanding its capabilities in new materials[106]. Market Trends and Industry Insights - The lubricating oil industry is experiencing diversification in application fields, driven by national policies promoting new quality productivity and high-quality development[39]. - The penetration rate of new energy vehicles reached 40.9% in 2024, indicating stable growth and expanding market share for low-viscosity synthetic ester products[41]. - The market for household air conditioning is recovering, with a V-shaped trend in sales, leading to increased demand for compatible refrigerants[41]. - In the pharmaceutical excipients industry, the government has introduced supportive policies to promote high-quality development, with a focus on smart manufacturing and high-end pharmaceutical excipients[36]. Risk Management and Compliance - The company has outlined potential risks in its management discussion and analysis section, emphasizing the importance of investor awareness[7]. - The company faces market risks due to increasing competition and regulatory changes in the pharmaceutical excipients industry[119]. - The company faces risks related to the supply and price volatility of key raw materials such as ethylene oxide and propylene oxide, which are crucial for production and closely tied to oil prices[123]. - Environmental protection regulations are becoming stricter, potentially increasing operational costs and impacting the company's financial performance if compliance is not maintained[123]. Corporate Governance and Management - The company has established a governance structure compliant with relevant laws and regulations, ensuring proper operation of the board and shareholder meetings[126]. - The company has approved various resolutions at the 2023 annual general meeting, including the 2023 financial report and profit distribution plan[126]. - The management team consists of experienced professionals from the industry, enhancing operational efficiency and strategic direction[52]. - The company has established specialized committees within the board, including the Audit Committee and the Compensation and Assessment Committee[138]. Employee and Shareholder Engagement - The company has implemented a structured compensation management system to enhance employee motivation and ensure sustainable development[145]. - The company emphasizes talent development through annual training plans and a certified internal trainer team to improve employee skills and management capabilities[146]. - The company plans to distribute a cash dividend of 4.00 RMB per 10 shares, totaling 54,175,652.80 RMB, which represents 37.00% of the net profit attributable to ordinary shareholders[151]. Environmental Responsibility - The company invested 6.9248 million yuan in environmental protection during the reporting period[159]. - Weir Biotech has a waste gas treatment capacity of 3000 m³/h for various pollutants, and all treatment facilities are operating normally[161]. - Both subsidiaries have obtained ISO 14001 environmental management system certification, ensuring effective environmental management practices[169]. - The company emphasizes sustainable development by optimizing production processes to reduce energy consumption and environmental impact[169].

证券代码：603351 证券简称：威尔药业 公告编号：2025-013 二、主要产品和原材料的价格变动情况 （一）主要产品销售价格变动情况 单位：元/吨（不含税） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京威尔药业集团股份有限公司（以下简称"公司"）主营业务为药用辅料及合 成润滑基础油产品的研发、生产和销售。根据上海证券交易所发布的《上市公司行 业信息披露指引第十四号－化工》等文件要求，现将公司 2025 年第一季度主要经营 数据公告如下： | 主要产品 | 2025 年 1-3 月 | 2025 年 | 1-3 月 | 2025 年 | 1-3 月 | | --- | --- | --- | --- | --- | --- | | | 生产量（吨） | | 销售量（吨） | 销售收入（万元） | | | 1、合成润滑基础油 | 15,781.08 | | 15,273.36 | | 24,264.46 | | 其中：机械类 | 10,706.87 | | 10,503.41 | | 18,637.12 | | 非机 ...

南京威尔药业集团股份有限公司 关于预计 2025 年度日常性关联交易情况的公告 010 证券代码：603351 证券简称：威尔药业 公告编号：2025- ● 是否需要提交股东大会审议：否 ● 日常关联交易对公司的影响：公司发生的日常关联交易是公司生产经营需要 发生的日常经营性业务往来，不会对公司独立性产生影响，公司的主营业务不会因 此类交易而对关联人形成依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 南京威尔药业集团股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开 第三届董事会第十一次会议，审议通过了《关于预计 2025 年度日常性关联交易情况 的议案》，关联董事均已回避表决，出席会议的非关联董事一致同意通过该议案。 第三届董事会独立董事第二次专门会议对该议案进行了事前审议，全体独立董 事一致审议通过，并发表如下意见： 重要内容提示： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | | | | | 2025 | 年/本年 1- | | | 本次预计金 | | --- | --- ...

南京威尔药业集团股份有限公司 董事会关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《上海证券交易所上市公司自 律监管指引第 1 号——规范运作》等要求，南京威尔药业集团股份有限 公司（以下简称"公司"）董事会，就公司在任独立董事管国锋先生、管 亚梅女士、魏明先生的独立性情况进行评估并出具如下专项意见： 2025 年 4 月 18 日 经核查公司现任独立董事管国锋先生、管亚梅女士、魏明先生的任职 经历以及签署的相关自查文件，上述人员未在公司担任除独立董事以外 的任何职务，也未在公司主要股东公司担任任何职务，与公司以及主要 股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系， 不存在影响独立董事独立性的情况。因此，公司独立董事符合《上市公 司独立 董事管理 办法》《 上海证券 交易所上市 公司自律 监管指引 第 1 号——规范运作》中对独立董事独立性的相关要求。 南京威尔药业集团股份有限公司董事会 ...

南京威尔药业集团股份有限公司（以下简称"公司"）聘请信永中和会计师事 务所（特殊普通合伙）（以下简称"信永中和"）作为公司 2024 年度审计机构。 根据财政部、国资委及证监会颁布的《国有企业、上市公司选聘会计师事务所管 理办法》（财会[2023] 4 号），公司对信永中和 2024 年度审计过程中的履职情况 进行评估。经评估，公司认为信永中和资质等方面合规有效，履职保持独立性， 勤勉尽责，公允表达意见。具体情况如下： 信永中和具有证券期货相关业务资格。截至 2024 年 12 月 31 日，信永中和 合伙人（股东）259 人，注册会计师 1780 人。签署过证券服务业务审计报告的 注册会计师人数超过 700 人。 2024 年年度审计过程中，信永中和就公司重大会计审计事项与专业技术部 及时咨询，按时解决公司重点难点技术问题。 2、意见分歧解决 信永中和 2023 年度业务收入为 40.46 亿元，其中，审计业务收入为 30.15 亿元，证券业务收入为 9.96 亿元。2023 年度，信永中和上市公司年报审计项目 364 家，收费总额 4.56 亿元，涉及的主要行业包括制造业，信息传输、软件和 信息技术服务业 ...

南京威尔药业集团股份有限公司 . 2024 年度 非经营性资金占用及其他关联资金往来的 专项说明 索引 页码 专项说明 非经营性资金占用及其他关联资金往来情况汇总表 您可使用手机"扫一扫"或进入"让码用于证明该审计报告是否由具有执业许可的会计师事务所出具 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mol.gov.cn)】 报告编码:京25ASDX2JS4 1 | | 信永中和会计师事务所 北京市东城区朝阳门北大街 联想话： +86(010)6554 288 | | +86(010)6554 2288 | | --- | --- | --- | --- | | | telephone: | 8号富华大厦A座9层 | | | Shine Winc | ShineWing | 9/F, Block A, Fu Hua Mansion, No_8, Chaoyangmen Beidajie, | | | | | Dongcheng District. Beijing, 1500. | +86(010)6554 7190 | | | certified nuhlic account ...

证券代码：603351 证券简称：威尔药业 公告编号：2025-009 南京威尔药业集团股份有限公司 关于公司及子公司向银行申请综合授信额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 4 月 18 日，南京威尔药业集团股份有限公司（以下简称"公司"）召开 第三届董事会第十一次会议，审议通过了《关于公司及子公司向银行申请综合授信 额度的议案》。为满足公司及子公司生产运营及业务发展的资金需求，公司及子公 司拟向银行申请不超过人民币 11 亿元的综合授信额度。综合授信方式包括但不限于 流动资金贷款、固定资产项目贷款、银行承兑汇票、信用证等。 上述授信额度并非公司及子公司实际融资金额。实际融资额将依据运营资金实 时需求，在授信额度范围内审慎确定，以与银行实际发生的融资额为准。公司及子 公司间可相互调剂使用额度，且在授信期限内，该授信额度可循环使用。 本议案尚需提交公司 2024 年年度股东大会审议。授信期限将自股东大会审议通 过之日起，至下一次审议通过相同事项之日止。董事会提请股东大会授权董事长及 转授权人士 ...